CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Designation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile in patients with wet age-related macular.
- NDA is supported by data evaluating seladelpar efficacy and safety in over 500 patients -
- Seladelpar is the first New Drug Application from CymaBay in its ongoing mission to help people.
CymaBay Therapeutics, Inc. , a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug.